Everand Logo

Welcome to Everand!

  • STAT

    A fatty liver drug from Gilead Sciences posts negative results in late-stage clinical trial

    by Adam Feuerstein Feb 11, 2019 1 minute
    Source: Eric Risberg/AP

    A readout from the first late-stage clinical trial intended to treat the fatty liver disease known as NASH has delivered disappointing results.

    Gilead Sciences said Monday that its experimental drug, called selonsertib, failed

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About A J&J Cough Syrup, A Pfizer And Moderna Patent Suit, And More
    A Johnson & Johnson children’s cough syrup found to contain unsafe levels of a toxic industrial solvent was sold in six African countries.
    STAT1 min read
    USDA Faulted For Disclosing Scant Information About Outbreaks Of H5N1 Avian Flu In Cattle
    With 28 herds in eight states infected with H5N1 bird flu, scientists are calling on the U.S. to release more data to help them assess the risk.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
    Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.

    Related Books & Audiobooks